The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.
 
Todd Michael Bauer
No Relationships to Disclose
 
Douglas Adkins
Consulting or Advisory Role - Pfizer (Inst)
Research Funding - Acerta Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cellceutix (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Soligenix (Inst); Sucampo Pharmaceuticals (Inst); VentiRx (Inst)
 
Gary K. Schwartz
Honoraria - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Novartis
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Novartis
Patents, Royalties, Other Intellectual Property - Patent pending regarding development of PNAs for targeted cancer therapy (new technology)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Novartis
 
Theresa Louise Werner
Research Funding - AbbVie (Inst); Bayer (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Ajjai Shivaram Alva
Honoraria - Eisai
Consulting or Advisory Role - Eisai
Research Funding - BIND Biosciences; Bristol-Myers Squibb; Genentech; Novartis; Oncogenex
 
David S. Hong
Research Funding - AstraZeneca (Inst); Eisai (Inst); Genentech (Inst); miRNA Therapeutics (Inst); Novartis (Inst); Pfizer (Inst)
 
Richard D. Carvajal
Consulting or Advisory Role - AstraZeneca; Aura Biosciences; Genentech; Janssen; Merck; Novartis
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Genentech (Inst); Immunocore (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst)
 
Mansoor N. Saleh
Honoraria - Genentech
Speakers' Bureau - Gilead Sciences; Novartis
Research Funding - Aileron Therapeutics (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst)
 
Lyudmila Bazhenova
Stock and Other Ownership Interests - Epic Sciences
Consulting or Advisory Role - AstraZeneca; Genoptix; Heat Biologics; Pfizer
Speakers' Bureau - Genentech; Novartis
 
Sanjay Goel
No Relationships to Disclose
 
Keith D. Eaton
No Relationships to Disclose
 
Robert D. Siegel
Honoraria - Janssen; Merck
 
Ding Wang
No Relationships to Disclose
 
Richard C. Lauer
No Relationships to Disclose
 
Saskia T.C. Neuteboom
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
 
Demiana Faltaos
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Arena Pharma; AstraZeneca; InVitae; Mirati Therapeutics
Research Funding - Mirati Therapeutics
 
Isan Chen
Employment - Mirati Therapeutics
Leadership - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
 
James Christensen
Employment - Mirati Therapeutics
Leadership - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics; Pfizer
Honoraria - Guardant Health
Consulting or Advisory Role - Guardant Health; Organovo
Patents, Royalties, Other Intellectual Property - Mirati Therapeutics; Pfizer
 
Richard C. Chao
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Merck; Mirati Therapeutics; Pfizer
 
Rebecca Suk Heist
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Abbvie; Celgene; Debiopharm Group; Exelixis; GlaxoSmithKline; Incyte; Millennium; Mirati Therapeutics; Novartis; Peregrine Pharmaceuticals; Roche; Sanofi